ENVB Stock — Enveric Biosciences Inc.: Cash, EV, Pipeline

Share price

$1.62

Market cap

$7.3M

Cash

$8.3M

Enterprise value

-$1.0M

Balance sheet

Cash	$8.3M
Debt	$0.0M
Net cash	$8.3M
Enterprise value	-$1.0M
Basic shares	3.9M shares
Fully diluted shares	11.4M shares
Fully diluted market cap	$18.5M
Cash per share	$2.13

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ENVB daily closes…

Loading price history…

Pipeline assets

EB-003

Preclinical · Active

Target 5-HT2A / 5-HT1B receptors

Partnerships License from Diverse Biotech (paid-up; no further liability on commercialization)

Indications

Difficult-to-address mental health disorders (depression, anxiety) (Preclinical)

Status note Lead drug candidate of the EVM301 Series; novel derivative of DMT (N,N-Dimethyltryptamine) designed to promote neuroplasticity without hallucinogenic effects. IND-enabling activities advanced in Q2 2026 toward planned first-in-human clinical studies; EVM401 Series remains a secondary focus.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	100,002	+100,002	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ENVB — Enveric Biosciences Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders